Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Xelox (Xeloda + Oxaliplatin) and Avastin for Metastatic Esophagogastric Adenocarcinoma (XAGastric)
This study is currently recruiting participants.
Study NCT00447330 Information provided by Duke University
First Received: March 13, 2007 Last Updated: April 17, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Esophageal Neoplasms
Stomach Neoplasms
Neoplasm Metastasis
Additional conditions recognized in this trial
Adenocarcinoma
Esophageal Diseases
Neoplasms
More general conditions related to this trial
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Head and Neck Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplastic Processes
Pathologic Processes
Stomach Diseases
Additional drug interventions recognized in this trial
Bevacizumab
Capecitabine
Oxaliplatin
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Duke University
Hoffmann-La Roche
Sanofi-Aventis
Genentech
Back to top of Main Content
